Literature DB >> 10623826

Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules.

Y Jun1, E Kim, M Jin, H C Sung, H Han, D E Geraghty, K Ahn.   

Abstract

The epidemiological correlation between human CMV (HCMV) infection and spontaneous fetal loss has been suggested, but the underlying mechanism is not well understood. Fetal cytotrophoblasts, which are in direct contact with the maternal immune system in the uterus during pregnancy, do not express HLA-A and HLA-B, but express the nonclassical class I HLA-G and HLA-C. It has been shown that both HLA-G and HLA-C are capable of inhibiting NK-mediated cell lysis. In our present study, using human trophoblast cell lines as well as other cell lines stably transfected with the human class I genes, we have demonstrated that HCMV US3 and US6 down-regulate the cell-surface expression of both HLA-G and HLA-C by two different mechanisms. HCMV US3 physically associates with both trophoblast class I MHC species, retaining them in the endoplasmic reticulum. In contrast, HCMV US6 inhibits peptide transport by TAP and thus specifically the intracellular trafficking of class I molecules. Therefore, these findings suggest for the first time a possible molecular mechanism underlying HCMV-related spontaneous pregnancy loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623826     DOI: 10.4049/jimmunol.164.2.805

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Structural and functional dissection of human cytomegalovirus US3 in binding major histocompatibility complex class I molecules.

Authors:  S Lee; J Yoon; B Park; Y Jun; M Jin; H C Sung; I H Kim; S Kang; E J Choi; B Y Ahn; K Ahn
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 2.  Emerging topics and new perspectives on HLA-G.

Authors:  Enrico Fainardi; Massimiliano Castellazzi; Marina Stignani; Fabio Morandi; Gwenaëlle Sana; Rafael Gonzalez; Vito Pistoia; Olavio Roberto Baricordi; Etienne Sokal; Josè Peña
Journal:  Cell Mol Life Sci       Date:  2010-11-16       Impact factor: 9.261

Review 3.  Heterogeneous pathways of maternal-fetal transmission of human viruses (review).

Authors:  A Saleh Younes; Márta Csire; Beatrix Kapusinszky; Katalin Szomor; Mária Takács; György Berencsi
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

4.  Human cytomegalovirus early protein pUL21a promotes efficient viral DNA synthesis and the late accumulation of immediate-early transcripts.

Authors:  Anthony R Fehr; Dong Yu
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 5.  Viral proteins interfering with antigen presentation target the major histocompatibility complex class I peptide-loading complex.

Authors:  Gustav Røder; Linda Geironson; Iain Bressendorff; Kajsa Paulsson
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

6.  Modulation of HLA-G expression in human neural cells after neurotropic viral infections.

Authors:  Monique Lafon; Christophe Prehaud; Françoise Megret; Mireille Lafage; Gaël Mouillot; Michèle Roa; Philippe Moreau; Nathalie Rouas-Freiss; Edgardo D Carosella
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 7.  Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.

Authors:  Mark R Schleiss
Journal:  Infect Disord Drug Targets       Date:  2011-10

Review 8.  CD8+ effector T cells at the fetal-maternal interface, balancing fetal tolerance and antiviral immunity.

Authors:  Tamara Tilburgs; Jack L Strominger
Journal:  Am J Reprod Immunol       Date:  2013-02-23       Impact factor: 3.886

Review 9.  Risks associated with viral infections during pregnancy.

Authors:  Karen Racicot; Gil Mor
Journal:  J Clin Invest       Date:  2017-05-01       Impact factor: 14.808

10.  Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells.

Authors:  Nagendra R Hegde; David C Johnson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.